- Aralez Pharmaceuticals (NASDAQ:ARLZ) announces that the national commercial launch of Zontivity (vorapaxar) in the U.S. will commence this week.
- Zontivity is a once-daily agent indicated for the reduction of thrombotic cardiovascular events in patients with a history of myocardial infarction (MI) or in patients with peripheral arterial disease (PAD), and should be used in combination with daily aspirin and/or clopidogrel according to their indications or standard of care.
- On April 24, the Company commenced its phased launch of Zontivity utilizing 15 sales representatives deployed to high volume physicians who treat post-MI and PAD patients. Also, 75 sales representatives will initially be covering ~25% of the oral antiplatelet market, targeting 12,000 physicians, including cardiologists, primary care and vascular surgeons.
- Now read: 2 Things Will Help Turn Around BioDelivery Sciences - Bret Jensen's Idea Of The Month
Original article